GeoVax director granted options for 6,000 shares

GeoVax Labs, Inc. director Randal D. Chase received a grant of stock options covering 6,000 shares of common stock.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

GeoVax Labs, Inc. director Randal D. Chase received a grant of stock options covering 6,000 shares of common stock. The options carry an exercise price of $1.18 per share, become exercisable on June 17, 2027, and expire on June 17, 2036. Following this award, he holds 6,000 options directly.

Insider Trade Summary

Grant/Award: 6,000 shares

Grant/Award 1 txn

Insider CHASE RANDAL D

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	6,000	$0.00	$0.00

Holdings After Transaction: Stock Option — 6,000 contracts (Direct)

Key Figures

Options granted: 6,000 options Exercise price: $1.18 per share Shares underlying options: 6,000 shares +2 more

5 metrics

Options granted 6,000 options Stock option award to director

Exercise price $1.18 per share Conversion or exercise price for options

Shares underlying options 6,000 shares Underlying common stock

Exercise date June 17, 2027 Options become exercisable

Expiration date June 17, 2036 Options lapse if unexercised

Key Terms

Stock Option, conversion or exercise price, expiration date, underlying security, +1 more

5 terms

Stock Option financial

"security_title: "Stock Option""

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

conversion or exercise price financial

"conversion_or_exercise_price: "1.1800""

expiration date financial

"expiration_date: "2036-06-17T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title: "Common Stock""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GeoVax (GOVX) disclose in this Form 4?

GeoVax disclosed that director Randal D. Chase received a grant of stock options for 6,000 shares of common stock. These options were awarded as compensation and do not represent an open-market purchase or sale of existing shares.

How many GeoVax (GOVX) options were granted to the director?

The director was granted stock options covering 6,000 shares of GeoVax common stock. This entire amount is reflected as held following the transaction, indicating the award increased his derivative holdings by the full 6,000 options.

What is the exercise price of the GeoVax (GOVX) stock options granted?

The granted GeoVax stock options have an exercise price of $1.18 per share. This is the price at which the director can purchase common shares upon exercising the options during the specified exercise period.

When do the newly granted GeoVax (GOVX) options become exercisable?

The stock options granted to the GeoVax director become exercisable on June 17, 2027. Before that exercise date, the options cannot be converted into common stock, so they function as a future right rather than current share ownership.

What is the expiration date of the GeoVax (GOVX) stock options?

The stock options granted to the GeoVax director expire on June 17, 2036. After this expiration date, any unexercised options will lapse, and the right to purchase common shares at $1.18 per share will end.

Did the GeoVax (GOVX) director buy or sell shares in the market?

The director did not buy or sell shares in the open market. The Form 4 reports a grant of stock options as compensation, coded as an acquisition (A), rather than a purchase or sale of existing common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/22/2026 - 04:19 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CHASE RANDAL D

(Last)

(First)

(Middle)

1955 LAKE PARK DRIVE

SUITE 300

(Street)

SMYRNA

GEORGIA

30080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GeoVax Labs, Inc. [ GOVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option	$1.18	06/17/2026		A		6,000		06/17/2027	06/17/2036	Common Stock	6,000	$0	6,000	D

Explanation of Responses:

	/s/ Randal D. Chase	06/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR